[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336577-105":59,"doc-detail-336577-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","first-case-report-of-sunvozertinib-for-the-treatment-of-her2-exon-20-insertion-in-lung-adenocarcinoma","First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma","","First case report describes a patient with HER2 exon 20 insertion lung adenocarcinoma and long-term exposure to multiple EGFR/HER2 tyrosine kinase inhibitors, all leading to drug resistance. After sunvozertinib 300 mg daily, respiratory distress and confusion improved within 3 days. Progression-free survival reached 87 days, followed by acquired resistance and death due to respiratory distress two months after discontinuation. The report highlights potential therapeutic value for HER2 exon 20 insertion patients after TKI failure.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-case-report-of-sunvozertinib-for-the-treatment-of-her2-exon-20-insertion-in-lung-adenocarcinoma/336577/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-case-report-of-sunvozertinib-for-the-treatment-of-her2-exon-20-insertion-in-lung-adenocarcinoma/336577.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical problem does this case report address?","Question",{"text":113,"@type":114},"It addresses treatment options for HER2-mutant non-small cell lung cancer, specifically HER2 exon 20 insertion, after multiple prior TKI failures and limited efficacy of existing targeted therapies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the patient respond after starting sunvozertinib?",{"text":118,"@type":114},"After sunvozertinib 300 mg daily, the patient’s respiratory condition improved and mental clarity returned within 3 days.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the progression-free survival and eventual outcome?",{"text":122,"@type":114},"The progression-free survival was 87 days. The patient later developed resistance and died due to respiratory distress two months after stopping sunvozertinib.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336577,1790144767,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":52},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Case report  \n757  \nFirst case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma  \nTao Luan, Xinqing Lin, Xiaohong Xie, Gang Yang, Shuaiying Wang, Jianqing Hao, Chengzhi Zhou  \nHuman epidermal growth factor receptor 2 (HER2) is atransmembrane glycoprotein receptor with intracellular tyrosine kinase activity. It is generally considered as a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), showed limited efficacy in HER2-mutant advanced nonsmall cell lung cancer (NSCLC). In the 2023 National Comprehensive Cancer Network guidelines for NSCLC, antibody-drug conjugate trastuzumab emtansine is recommended for the treatment of HER2-mutant lung cancer. However, this medication is currently not approved in certain regions. So it is necessary to explore alternative treatment options for HER2-mutant NSCLC patients. In our study of a patient with HER2 exon 20 insertion lung adenocarcinoma who had previously failed multiple epidermal growth factor receptor (EGFR)-TKI treatments, we discovered that sunvozertinib could stabilize the patient’s condition,  \nachieving a progression-free survival of 87 days. This is a novel finding that may provide new treatment options for HER2 exon 20 insertion patients who have failed TKI therapy. Anti-Cancer Drugs 35: 757–760 Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.  \nAnti-Cancer Drugs 2024, 35:757–760  \nKeywords: case report, gene mutation, novel therapy, targeted therapy  \nThe First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou 510000, China  \nCorrespondence to Chengzhi Zhou, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou 510000, China.  \ne-mail: [doctorzcz@163.com](doctorzcz@163.com)  \nReceived 23 February 2024 Revised form accepted 23 February 2024.  \nIntroduction  \nThis article presents a patient with a 16-year history of Human epidermal growth factor receptor 2 exon 20 insertion (HER2 exon20ins) lung adenocarcinoma. After the administration of various tyrosine kinase inhibitors (TKIs), including gefitinib, poziotinib, cabozantinib, and lenvatinib, all of them resulted in drug resistance. Eventually, the patient developed respiratory distress and confusion. After initiating treatment with sunvozertinib at a dose of 300 mg Qd, the patient’s respiratory condition improved, and mental clarity was restored after 3 days. However, after 3 months, the patient developed resistance to sunvozertinib with a progression-free survival (PFS) of 87 days. Ultimately, the patient died due to respiratory distress 2 months after discontinuing sunvozertinib.  \nCase report  \nA 67-year-old, female patient, non-smoker, diagnosed with lung adenocarcinoma 16 years ago, was admitted to the hospital due to sudden onset of ‘shortness of breath and altered consciousness’. The patient has no family history of cancer or infectious diseases and  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBYNC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.  \nhas normal psychological and mental status. In 2007, the patient’s routine examination revealed lung adenocarcinoma, Stage IIIa, T2N2M0 . From May 2008 to December 2020, the patient was treated with gefitinib 250 mg/Qd for 12 years, with two rounds of adjuvant radiotherapy during this period, and the tumor progressed slowly. The","cbCaieE2k2CGUIwZ","https://ap.wps.com/l/cbCaieE2k2CGUIwZ","pdf",557116,"English","# Introduction\n# Case report","[{\"question\":\"What clinical problem does this case report address?\",\"answer\":\"It addresses treatment options for HER2-mutant non-small cell lung cancer, specifically HER2 exon 20 insertion, after multiple prior TKI failures and limited efficacy of existing targeted therapies.\"},{\"question\":\"How did the patient respond after starting sunvozertinib?\",\"answer\":\"After sunvozertinib 300 mg daily, the patient’s respiratory condition improved and mental clarity returned within 3 days.\"},{\"question\":\"What was the progression-free survival and eventual outcome?\",\"answer\":\"The progression-free survival was 87 days. The patient later developed resistance and died due to respiratory distress two months after stopping sunvozertinib.\"}]","First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma | PDF",1790015704]